A date for your diary: the next course an “Update on Pharmacoeconomics in the Irish Healthcare Setting” will take place on Friday 21 October 2022 from 9am to 4pm at the Convention Centre Dublin (CCD). Full programme will follow shortly. Registration form 2022
The NCPE recommends that ravulizumab (Ultomiris®), for the treatment of adult patients with PNH, be considered for reimbursement provided certain conditions are met.*
The NCPE recommends that andexanet alfa (Ondexxya®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.